BELLEVUE, Wash. - Novo Integrated Sciences, Inc. (NASDAQ:NVOS), a company engaged in a multidisciplinary healthcare ecosystem, has announced the appointment of Mr. Robert Oliva as its new President.
Mr. Oliva brings over 35 years of experience in business development and manufacturing operations to the role. He will be succeeding Mr. Christopher David, who will continue in his position as the Chief Operating Officer and maintain his seat on the Board of Directors.
The company's CEO and Board Chairman, Robert Mattacchione commented, "The addition of Mr. Oliva comes at a time when the Company is focusing significant energy and resources in ramping up our manufacturing and product offerings. His years of building a manufacturing business, from the ground up, into a significant, profitable enterprise will be an enormous asset in providing oversight and guidance to the Company's leadership team."
Novo Integrated Sciences is known for its holistic approach to healthcare, integrating medical technology, advanced therapeutics, and rehabilitative science to provide patient-first health and wellness services.
The company's approach to decentralizing healthcare aims to shift non-critical care from primary medical centers to patients' homes, leveraging advancements in medical technology and interconnectivity. This model is intended to prevent the escalation of non-critical health conditions and provide more cost-effective healthcare distribution.
The information in this article is based on a press release statement from Novo Integrated Sciences.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.